Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valbenazine for Chorea Associated With Huntington Disease
NCT04400331Phase 3Terminated
- Sponsor
- Neurocrine Biosciences
- Start
- Sep 2020
- Primary completion
- Nov 2025
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of valbenazine in Huntington disease (HD), sponsored by Neurocrine Biosciences. Started Sep 2020; status: terminated.
02
Drugs
valbenazine
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NCT04400331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04400331.